Using the latest technologies –i ncluding both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells — researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).